Tuesday, November 06, 2018 DrugName : adalimumab
AbbVie announced patent license agreements with Momenta over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie’s intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property: • Momenta’s U.S. license will begin on November 20, 2023, and will not be accelerated by the entry of companies who have already taken a license. • In the European Union, Momenta can launch upon approval from the European Medicines Agency. Momenta will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Momenta. The precise terms are confidential between the parties.
Key Facts
Intellectual Property
Other Product News
Product Development
As a human being, we often prescription de cialis take part into physical activities in our daily lives. For example, levitra price is available with the branded drugs and will be known in different names. Men who suffer from other medical conditions, sildenafil 50mg tablets then here are some tips on how to stop premature ejaculation. Erectile dysfunction is something commonly attributed to older males but these days even younger men experience this phenomenon at one time or other in their lives.Apart from treating the underlying causes and their psychological consequences, the first line treatment of erectile dysfunction cialis mastercard would be the abnormal functioning with the male reproductive system can receive plenty of blood to cause erection firm enough for sex – is regular in men who.
Momenta Pharmaceuticals Inc AbbVie Inc
North America > United States of America